Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy Pharmaceutical TechnologyCellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan's TSC-101 therapy in AML and MDS patients.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaceutical Technology Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients. Oncology Read full story Post navigation Previous: A Spanish biotech banks $87M to make differentiated ADCsNext: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026